- Home
- CNSP vs LCFY Comparison
CNSP vs LCFY Comparison
Compare CNSP & LCFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNSP
- LCFY
- Stock Information
- Founded
- CNSP 2017
- LCFY 2009
- Country
- CNSP United States
- LCFY Australia
- Employees
- CNSP N/A
- LCFY N/A
- Industry
- CNSP Biotechnology: Pharmaceutical Preparations
- LCFY
- Sector
- CNSP Health Care
- LCFY
- Exchange
- CNSP Nasdaq
- LCFY Nasdaq
- Market Cap
- CNSP 6.5M
- LCFY 7.3M
- IPO Year
- CNSP 2019
- LCFY 2022
- Fundamental
- Price
- CNSP $0.10
- LCFY $7.51
- Analyst Decision
- CNSP Strong Buy
- LCFY
- Analyst Count
- CNSP 1
- LCFY 0
- Target Price
- CNSP $0.50
- LCFY N/A
- AVG Volume (30 Days)
- CNSP 29.2M
- LCFY 27.3K
- Earning Date
- CNSP 03-31-2025
- LCFY 11-12-2024
- Dividend Yield
- CNSP N/A
- LCFY N/A
- EPS Growth
- CNSP N/A
- LCFY N/A
- EPS
- CNSP N/A
- LCFY N/A
- Revenue
- CNSP N/A
- LCFY $2,668,385.00
- Revenue This Year
- CNSP N/A
- LCFY N/A
- Revenue Next Year
- CNSP N/A
- LCFY N/A
- P/E Ratio
- CNSP N/A
- LCFY N/A
- Revenue Growth
- CNSP N/A
- LCFY N/A
- 52 Week Low
- CNSP $0.08
- LCFY $2.20
- 52 Week High
- CNSP $23.90
- LCFY $11.23
- Technical
- Relative Strength Index (RSI)
- CNSP 41.60
- LCFY 54.42
- Support Level
- CNSP $0.09
- LCFY $7.00
- Resistance Level
- CNSP $0.10
- LCFY $9.39
- Average True Range (ATR)
- CNSP 0.01
- LCFY 0.62
- MACD
- CNSP -0.00
- LCFY -0.06
- Stochastic Oscillator
- CNSP 43.33
- LCFY 49.62
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About LCFY Locafy Limited
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has three operating segments: the Publishing segment, the Reseller segment, and the Channel sales segment. It derives a majority of its revenue from Australia and New Zealand.